Purity >98% by HPLC. Lenvatinib is a potent inhibitor of multiple receptor tyrosine kinases, with IC50 values of 22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRBeta and RET, respectively. It inhibits SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC50 values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibits tumor growth in the human small cell lung cancer H146 xenograft model.